CN103830730A - Budesonide/H1 receptor antagonist compound inhalant - Google Patents
Budesonide/H1 receptor antagonist compound inhalant Download PDFInfo
- Publication number
- CN103830730A CN103830730A CN201210494863.XA CN201210494863A CN103830730A CN 103830730 A CN103830730 A CN 103830730A CN 201210494863 A CN201210494863 A CN 201210494863A CN 103830730 A CN103830730 A CN 103830730A
- Authority
- CN
- China
- Prior art keywords
- compound medicine
- suction compound
- suction
- receptor antagonist
- medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
The invention relates to a budesonide/H1 receptor antagonist compound inhalant which contains budesonide and one or more H1 receptor antagonists used as active components, and one or more pharmaceutical auxiliary materials suitable for inhalation administration. The H1 receptor antagonist is one or more of loratadine, desloratadine, cetirizine, levocetirizine, astemizole, ketotifen, ebastine, fexofenadine, avastin, mequitazine, mizolastine and salts thereof, and preferably one or more of loratadine, desloratadine, cetirizine, levocetirizine, ebastine, mizolastine, avastin, mequitazine, ketotifen and hydrochlorides or fumarates thereof.
Description
Technical field:
The present invention relates to the compound recipe composition for inhalation that contains glucocorticoid H1 receptor antagonist.
Background technology:
Glucocorticoid has antiinflammatory, antiallergic, rheumatism, immunosuppressive action, is widely used in treatment anaphylaxis and autoimmune inflammation disease.As connective tissue disease, activeness rheumatism, rheumatoid arthritis, lupus erythematosus, serious bronchial asthma, serious dermatitis, ulcerative colitis, acute leukemia etc., also for some severe infections and Comprehensive Treatment poisoning, malignant lymphoma.
Asthma is a kind of chronic airway inflammation, it is characterized by Reversible airway obstruction and airway reactivity increases, and secretions increase, myxedema and two kinds of factors of inflammatory stimulus smooth muscle spasm that airway obstruction is caused by bronchial mucosa inflammation cause; And airway reactivity to increase be also the result of the bronchial epithelial cell damage that causes due to airway inflammation.People recognize to only have the inflammation of controlling air flue mucosa, just can reach the object of final reduction airway hyperreactivity, relieving asthma symptoms.The medicine for the treatment of at present the pulmonary disease such as asthma mainly contains following several: (1) broxaterol, (2) xanthine drug, (3) anticholinergic agent, (4) glucocorticoid, (5) antiallergic agent.China's document " inhaled corticosteroids is for learning and pharmacodynamics " (Wang Changzheng, practical hospital clinical magazine, the 4th the 1st phase of volume of January in 2007,16-18) point out, sucking parahormone (ICS) has become the first-line drug of asthma long-term treatment, as ciclesonide, fluticasone propionate, momestasone furoate, budesonide etc.The document also points out, desirable ICS should be the perfect adaptation of effectiveness and safety, although ICS compared with general hormone in existing huge progress aspect the safety for the treatment of, still can not meet well the needs of clinical treatment.Long-term, high-dose uses ICS still to there will be the untoward reaction such as adrenal cortex function inhibition, and uses separately the ICS (inferior heavy dose) of so-called safe dose can't effectively control severe asthma in majority.
Histamine is a kind of chemical mediator, is present in the in-house mastocyte of human body and the basophil of blood.When these cells are subject to after immunity reason or the stimulation of other chemical factors, antigen is combined with the IgE of cell surface, makes a large amount of histamine of the injured release of cell etc.Histamine causes that by H1 and the H2 receptor of each histoorgan skin and mucosa telangiectasis and permeability increase, and produces erythema and welt; Cerebral vasodilators (headache); Blood pressure drops; Heart rate accelerates and heart output increases; Make bronchus and gastrointestinal smooth muscle spasm; Gastric secretion increases; The histamine tip that excites nerve also causes pruritus and pain.
H1 receptors bind on H1 receptor antagonist selectivity and histamine target cell, blocking histamine H1 receptor and bring into play antihistamine effect; Adhesion molecule is to participate in body inflammatory reaction and immunoreactive important component, the inflammatory reaction that antihistamine drug energy anti-adhesion is numerator mediated.H1 receptor antagonist can be according to its onset speed, and having or not of Pharmacokinetic Characteristics and the selectivity to H1 receptor and sedation, is divided into the first generation and the second filial generation.
H1 receptor antagonist also has side effect in having antianaphylactic effect, and wherein the most outstanding is central inhibitory action, as drowsiness etc., no matter is that the first generation or second filial generation H1 receptor antagonist all have similar untoward reaction.
This kind of untoward reaction is mainly because H1 receptor antagonist in use all adopts the drug systemic administration route such as oral, drug dose is larger simultaneously, substantially all more than 5mg/ days, in performance anti-allergic effects, also can produce untoward reaction to central nervous system.
Summary of the invention:
The discovery that we are surprised, in the time that micro-H1 receptor antagonist is made suction preparation, in the time of budesonide composition compound medicine, in the time for the treatment of asthma, also can produce good effect, curative effect is more obvious, its effect had both been better than independent inhalation of budesonide or H1 receptor antagonist, was also better than and successively sucked two kinds of medicines, illustrated that both have produced synergy while suction at the same time.
A kind of compound medicine that sucks, contain budesonide and one or more H1 receptor antagonists as active component, and one or more is applicable to the pharmaceutic adjuvant of inhalation.
Described H1 receptor antagonist is one or more in loratadine, Desloratadine, cetirizine, levocetirizine, astemizole, ketotifen, ebastine, fexofenadine, acrivastine, Primalan, mizolastine and salt thereof.Be preferably one or more in loratadine, Desloratadine, cetirizine, levocetirizine, ebastine, mizolastine, acrivastine, Primalan, ketotifen and hydrochlorate thereof, fumarate.More preferably one or more in loratadine, Desloratadine, cetirizine hydrochloride, levo-cetirizine hydrochloride.
Described suction compound medicine, the weight proportion of budesonide and H1 receptor antagonist is 1:0.1-10.Be preferably 1:0.5-5.
Described suction compound medicine is powder spray or aerosol.Be preferably powder spray.Described powder spray, the D90 particle diameter of active component is 1～10 μ m.Preferably D90 particle diameter is 5～10 μ m.
Described powder spray, described pharmaceutic adjuvant comprises one or more in carrier, additives.Described carrier is one or more in saccharide, aminoacid, lecithin, phosphatidylcholine.
Described aminoacid is one or more in glycine, valine, leucine.
Described saccharide is monosaccharide, disaccharide, derived carbohydrate, monosaccharide is mannitol, fructose, glucose, described disaccharide is maltose, trehalose, cellobiose, lactose, sucrose, and described derived carbohydrate is eight acetate fiber two sugar esters, sucrose octa-acetate, eight acetic acid lactose esters, five acetic acid glucose esters, six acetic acid Nitranitols and eight acetic acid Sargassum sugar esters.
Described carrier is one or both the combination in saccharide and lecithin, phosphatidylcholine.Preferably lactose.
Described additives comprise one or more in surfactant, lubricant, antistatic additive.The preferred poloxamer of described surfactant.Described lubricant is one or more in magnesium stearate, micropowder silica gel, Pulvis Talci.
Described powder spray, the mean diameter of described carrier is 25～75 μ m.Be preferably 30～55 μ m.
Described powder spray, is characterized in that the summation of described active component and the weight ratio of carrier are 1:10 ~ 100.Be preferably 1:10 ~ 50.
Described powder spray, the mode subpackage take the packaged of single or multiple dosage as capsule.Capsule is plant capsule.
Described suction compound medicine, preparation becomes aerosol, and described pharmaceutic adjuvant comprises pharmaceutically useful propellant and other optional additives of being applicable to aerosol.Described propellant is one or more in fluorohydrocarbon compounds.Be preferably a kind of or its combination in HFA 134a (HFA134a) and 1,1,1.2,3,3,3-heptafluoro-propane (HFA 227).Particularly preferably HFA134a.
Described aerosol, comprises solvent in described additives, is selected from glycerol, one or more in propylene glycol, Polyethylene Glycol, ethanol or oleic acid.Preferred alcohol.Described active component is that D90 particle diameter is the micropowder of 0.5-10 μ m.
Described suction compound medicine, the dosage of H1 receptor antagonist is 50-1000 μ g/ time.Preferably 50-500 μ g/ time.
Described suction compound medicine, the consumption of H1 receptor antagonist is 100-1600 μ g/ days.Preferably 100-800 μ g/ days.
Described suction compound medicine, the application in the medicine of preparation treatment asthma.
Packaged that can single or multiple dosage when aforementioned pharmaceutical compositions is prepared into powder spray.
The preparation method of described aerosol is: to the active component micropowder that adds recipe quantity in aerosol bottle, open the valve on bottle, the mixture of premixed propellant and optional additives is imported by valve, valve-off, obtains required aerosol.Optional aerosol bottle is carried out to ultra sonic bath with solubilising
Or can adopt following preparation method: micronized active component is distributed in additives, then adds in the propellant after pre-cooling and mix, then divide and install in aerosol bottle.
Should be appreciated that because of known reason, as the retention of active component in suction apparatus, the amount of every kind of active component that patient sucks can be different from the amount of metering.Therefore the applicating ratio between active component can be different from the ratio of metering.The ratio of preferably using is in the described metered proportions indicating.
Described aerosol bottle and valve system can be selected disclosed aerosol bottle and valve system in Chinese patent CN98805261.X.
In this patent, the dosage of said medicine, with the weighing scale of medicine itself, does not comprise the weight of its salt or ester, and for example cetirizine hydrochloride 100mg, in fact refers to cetirizine 100mg, rather than the hydrochlorate 100mg of cetirizine.
Particle diameter in the present invention is equivalent volume footpath, is the diameter of the ball identical with actual particle volume.It is generally acknowledged that the diameter that laser method is surveyed is equivalent volume footpath.
D90 particle diameter refers to corresponding particle diameter when the cumulative particle sizes distribution number of a sample reaches 90%.Its physical significance be particle diameter be less than it amounts of particles account for 90%, this numerical value can detect by laser particle instrument.
Mean diameter refers to meso-position radius, can detect with laser particle analyzer.
The specific embodiment
Micronization of the present invention can use known mechanical crushing method or spray drying method.Mechanical crushing method refers to and utilizes the method for fluid energy mill (using the QM-3A of Nanjing Univ. Instrument Factory) respectively medicine and/or carrier powder to be broken into needed particle diameter.Spray drying method refers to medicine and/or carrier is dissolved in to organic solvent entirely as in ethanol, process spray dryer (as Buli Minispray, 190 types, Germany or QW-500, Xishan city Lin Zhou drying machine factory), solid material is made to needed particle diameter.Use and can also add when spray drying method surfactant as poloxamer etc.The process conditions of spray drying method can be: inlet temperature is 105 ℃, and outlet temperature is 68 ℃, throughput 90%, and jet expansion internal diameter is 0.1cm, nozzle air flow velocity 800ml/min, sample introduction speed 50mL/h.
Powder spray adopts No. 3 plant capsules (sino-america joint-venture Suzhou Capsule Co., Ltd produces, trade name: Vcaps), and each embodiment feeds intake according to 1000 capsules.It is aluminum-plastic packaged that the capsule of powder spray packs bubble-cap type into, when use, takes out, and packs powder spray inhaler (Shanghai balance pharmaceutical factory) into and use.
Medicine mist (dripping) the grain abundance of measuring in embodiment is below to detect according to the method in 2010 editions pharmacopeia appendix XH.
Embodiment 1
By H1 receptor antagonist, other active component fluid energy mill micronization, Lactis Anhydrous 10g is micronized to mean diameter 56 μ m with fluid energy mill, after mixing, crosses after 200 mesh sieve mixes for 3 times and is divided in 1000 No. 3 capsules.
Reference examples 1-1～reference examples 1-25, for according to the composition and engineering of embodiment 1 corresponding numbering embodiment, the H1 receptor antagonist composition for inhalation that does not add budesonide to be prepared into.(being the corresponding embodiment 1-1 of reference examples 1-1, the corresponding embodiment 1-5 of reference examples 1-5, the corresponding embodiment 1-6 of reference examples 1-6).
Reference examples 2-1～reference examples 2-25, for according to the composition and engineering of embodiment 1 corresponding numbering embodiment, the budesonide composition for inhalation that does not add H1 receptor antagonist to be prepared into.(being the corresponding embodiment 1-1 of reference examples 2-1, the corresponding embodiment 2-5 of reference examples 2-5, the corresponding embodiment 2-6 of reference examples 2-6).
The preparation of aerosol, ethanol used is 95% ethanol, active component used is 0.5-10 μ m for being micronized to particle diameter.
Embodiment 2
Active component
Ethanol 500g
HFA227 1000.g
Preparation technology: recipe quantity active component is added to ethanol, stir, divided dose fill, sealing-in dosage valve system, HFA227 is injected in pressurization more respectively, to obtain final product.
Embodiment 3
Active component
Ethanol 500g
HFA134a 1098g
Preparation technology: the active component of recipe quantity is added to ethanol, stir, divided dose fill, sealing-in dosage valve system, HFA134a is injected in pressurization more respectively, to obtain final product.
Pharmacology embodiment 1 asthma pharmacological evaluation
1, animal model
Choose male Wistar rat, body weight is 200 ± 10g, puts into the bell glass of 5 liters of left and right, sprays into 2% acecoline and 0.1% 15 seconds of histamine phosphate's volume mixed liquor with the pressure of 400mmHg.After spraying stops, observing the drawing and breathe heavily incubation period of rat (asthma occur, breathe and be the devil, until twitch the time of falling), draw and breathe heavily the phase of diving and be less than 70 seconds or be greater than the rat of 120 seconds and will not select.
2, experimental technique
Learn from else's experience to measure to draw and breathe heavily qualified rat incubation period, carry out random packet according to the group in following table, every group 10, model group 1 gives according to inhalation route the Lactis Anhydrous that mean diameter is 55 μ m, dosage is 10mg/kg, other give respectively the medicine that embodiment and reference examples obtain, once a day, inhalation, grouping sees the following form with dosage, dosage 1 is H1 receptor antagonist agent dose, dosage 2 is budesonide dosage, unit is μ g/kg, matched group 2-1～matched group 2-25 is after the H1 receptor antagonist 10min giving according to inhalation route in reference examples 1-1～1-25, resorb the glucocorticoid of reference examples 2-1～2-25, effective ingredient dosage with identical with matched group 1-1～matched group 1-25 respectively (be that matched group 2-1 is identical with matched group 1-1, matched group 2-5 is identical with matched group 1-5, the rest may be inferred).
The 4th day of administration give 0.25% 2 hydrochloric acid histamine when giving after whole medicines spraying after 1.5 hours, observe to drawing before and after medicine and breathe heavily preclinical variation (draw while breathing heavily animal and do not occur in 6 minutes that the person of falling breathes heavily the volt phase and calculated as 360 seconds to draw).
Table sucks the impact (n=10, mean ± SD) of induction asthma attack on histamine phosphate's spraying
4, conclusion: suck compound medicine by the table visible budesonide of l and H1 receptor antagonist and can obviously extend the Experimental Asthma In Guinea-pigs outbreak incubation period of histamine phosphate's induction, with independent inhalation of budesonide or H1 receptor antagonist, and successively suck both and compare, suction compound medicine provided by the invention, can obviously extend to draw and breathe heavily incubation period, determined curative effect has clinical use value very much.
Pharmacology embodiment 2 nervus centralis untoward reaction pharmacological evaluation
2.1 laboratory animals: Kunming mouse, body weight 20 ± 2g.
2.2 instrument JZZ98-CM mice activity inventory instrument, RM86 Xing Ba road physiograph.
The experimental technique of 2.3 impacts on central nervous system
2.3.1.1 on the freely impact of activity of mice
Get Kunming mouse, male and female half and half, by body weight random packet, every group 10, give respectively the medicine of corresponding dosage with gavage, suction according to following table, blank group 1 gives 1%CMC-Na (sodium carboxymethyl cellulose) solution 20ml/kg gavage, and blank group 2 gives 5mg/kg lactose and sucks.After 10 minutes, put into JZZ98-CM mice activity inventory instrument with administration, record is take 10 minutes as unit record mice autonomic activities number of times and observe the variation of its outward appearance behavior, and continuous record 60 minutes, gets minimum and add up.
2.3.1.2 on the freely experimental result of movable impact of mice
The impact of 2.3.2.1 falling asleep on giving the mice of subliminal hypnosis metering pentobarbital sodium
Get Kunming mouse, male and female half and half, by body weight random packet, every group 10, give respectively the medicine of corresponding dosage with gavage, suction according to following table, blank group 1 gives 1%CMC-Na (sodium carboxymethyl cellulose) the solution 20ml/kg of same volume, and blank group 2 gives 5mg/kg lactose and sucks.After inhalation behind 30 minutes, oral administration 60 minutes, all at lumbar injection pentobarbital sodium 30mg/kg, above as the index of falling asleep using righting reflex loss 1min, observe in 10min each treated animal number of falling asleep, the calculating quantity of falling asleep.
The experimental result of impact 2.3.2.2 mice falls asleep
Can prove by above-mentioned untoward reaction experiment, compound preparation provided by the invention, the untoward reaction of nervus centralis is less compared with oral H1 receptor antagonist.
Claims (10)
1. suck a compound medicine, contain budesonide and one or more H1 receptor antagonists, and one or more are applicable to the pharmaceutic adjuvant of inhalation.Described H1 receptor antagonist is one or more in loratadine, Desloratadine, cetirizine, levocetirizine, astemizole, ketotifen, ebastine, fexofenadine, acrivastine, Primalan, mizolastine and salt thereof.
2. suction compound medicine as claimed in claim 1, is characterized in that described suction compound medicine is powder spray or aerosol.
3. suction compound medicine as claimed in claim 2, is characterized in that described powder spray, and described pharmaceutic adjuvant comprises one or more in carrier, additives.
4. suction compound medicine as claimed in claim 2, is characterized in that described saccharide is monosaccharide, disaccharide, derived carbohydrate, and monosaccharide is mannitol, fructose, glucose, and described disaccharide is maltose, trehalose, cellobiose, lactose, sucrose.
5. suction compound medicine as claimed in claim 3, is characterized in that described carrier is one or both the combination in saccharide and lecithin, phosphatidylcholine.
6. suction compound medicine as claimed in claim 3, is characterized in that described additives comprise one or more in surfactant, lubricant, antistatic additive.
7. suction compound medicine as claimed in claim 6, is characterized in that the preferred poloxamer of described surfactant.
8. suction compound medicine as claimed in claim 6, is characterized in that the mean diameter of described carrier is 25～75 μ m.
9. suction compound medicine as claimed in claim 6, is characterized in that described powder spray, the mode subpackage take the packaged of single or multiple dosage as capsule.
10. suction compound medicine as claimed in claim 2, preparation becomes aerosol, it is characterized in that described pharmaceutic adjuvant comprises pharmaceutically useful propellant and other additives of being applicable to aerosol.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210494863.XA CN103830730A (en) | 2012-11-26 | 2012-11-26 | Budesonide/H1 receptor antagonist compound inhalant |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210494863.XA CN103830730A (en) | 2012-11-26 | 2012-11-26 | Budesonide/H1 receptor antagonist compound inhalant |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103830730A true CN103830730A (en) | 2014-06-04 |
Family
ID=50794830
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210494863.XA Pending CN103830730A (en) | 2012-11-26 | 2012-11-26 | Budesonide/H1 receptor antagonist compound inhalant |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103830730A (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101102760A (en) * | 2003-09-15 | 2008-01-09 | 康宾纳特克斯公司 | Methods and reagents for the treatment of immunoinflammatory disorders |
| CN102247597A (en) * | 2010-05-19 | 2011-11-23 | 天津金耀集团有限公司 | Novel inhalant containing glucocorticoid and bronchodilator |
-
2012
- 2012-11-26 CN CN201210494863.XA patent/CN103830730A/en active Pending
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101102760A (en) * | 2003-09-15 | 2008-01-09 | 康宾纳特克斯公司 | Methods and reagents for the treatment of immunoinflammatory disorders |
| CN102247597A (en) * | 2010-05-19 | 2011-11-23 | 天津金耀集团有限公司 | Novel inhalant containing glucocorticoid and bronchodilator |
Non-Patent Citations (1)
| Title |
|---|
| 崔福德: "《药剂学》", 31 January 2006 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103269694A (en) | Pharmaceutical composition | |
| CN101801378A (en) | Novel combination of therapeutic agents | |
| CN1972730A (en) | Glycopyrrolate for treating childhood asthma | |
| JP2014516062A (en) | Combinations containing umecridinium and corticosteroids | |
| CN104208076A (en) | Compound inhalation preparation containing cephalosporin antibiotic and glucocorticoid | |
| WO2015173153A1 (en) | Combinations of tiotropium bromide, formoterol and budesonide for the treatment of copd | |
| KR101475262B1 (en) | Compound composition for inhalation used for treating asthma | |
| JP2017530993A (en) | Composition comprising at least one dry powder obtained by spray drying to enhance the stability of the formulation | |
| US20100210611A1 (en) | Combination therapy | |
| CN103830208A (en) | H1-receptor-antagonist-containing inhalation preparation | |
| JP6415536B2 (en) | Pharmaceutical composition comprising budesonide and formoterol | |
| CN103830730A (en) | Budesonide/H1 receptor antagonist compound inhalant | |
| CN103830729A (en) | Fluticasone and fluticasone ester/H1 receptor antagonist inhalant | |
| CN103830728A (en) | Compound inhalation medicine of ciclesonide and H1 receptor antagonist | |
| CN103830727A (en) | Compound inhalation medicine of mometasone furoate and H1 receptor antagonist | |
| CN104758294A (en) | Inhalation pharmaceutical composition used for treatment of chronic obstructive pulmonary disease (COPD) and asthma and preparation method thereof | |
| CN103830731A (en) | Glucocorticoid/H1 receptor antagonist compound inhalation composition | |
| CN104274427A (en) | Novel aerosol formulations of granisetron and uses thereof | |
| CN104208045A (en) | Compound inhalation preparation containing penicillin antibiotic and glucocorticoid | |
| CN104208688A (en) | Pharmaceutical composition containing individually-packaged mometasone furoate and epinephrine beta2-acceptor stimulant placed in inhalation device for synchronous application | |
| CN104208690A (en) | Pharmaceutical composition containing individually-packaged ciclesonide and epinephrine beta2-acceptor stimulant placed in inhalation device for synchronous application | |
| CN102850426B (en) | A kind of 21 is the glucocorticosteroid of N-acetylcystein ester | |
| CN104208687A (en) | Dry powder inhalation pharmaceutical composition containing different active components packaged in inhalation device for synchronous application | |
| CN104208060A (en) | Compound inhalation preparation containing penicillin antibiotic | |
| CN104208689A (en) | Pharmaceutical composition containing individually-packaged budesonide and epinephrine beta2-acceptor stimulant placed in inhalation device for synchronous application |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20140604 |